Epidemiology of heart failure with preserved ejection fraction.
Epidemiology of heart failure with preserved ejection fraction.
复制标题
DOI：
10.1007/s11897-014-0223-7
复制
发表时间：
2014-12-01
影响因子：
--
通讯作者：
Agarwal, Sunil K
中科院分区：
文献类型：
--
作者：
Dhingra, Abhinav;Garg, Aayushi;Agarwal, Sunil K
由于人口老龄化，心力衰竭（HF）及其亚型——保留射血分数（HFpEF）的患病率呈上升趋势。HFpEF是几种病理生理过程的汇合，目前尚未明确识别。HFpEF通常与全身性疾病相关，如糖尿病、高血压、心房颤动、睡眠呼吸暂停、肾脏和肺部疾病。HF患者合并HFpEF的比例因患者人口统计学、研究环境（队列vs临床试验、门诊vs住院患者）和用于定义保留功能的切点而异。关于HFpEF患者心血管和非心血管合并症的患病率和预后意义的文献越来越多。目前的治疗方法旨在减轻症状，治疗相关的合并症，并减少复发住院。缺乏循证疗法表明HFpEF患者死亡率降低；然而，在很少的干预下，运动耐受性和生活质量得到了改善。在这篇综述中，我们重点介绍了HFpEF的流行病学和目前的治疗方案。
The prevalence of heart failure (HF) and its subtype, HF with preserved ejection fraction (HFpEF), is on the rise due to aging of the population. HFpEF is convergence of several pathophysiological processes, which are not yet clearly identified. HFpEF is usually seen in association with systemic diseases, such as diabetes, hypertension, atrial fibrillation, sleep apnea, renal and pulmonary disease. The proportion of HF patients with HFpEF varies by patient demographics, study settings (cohort vs. clinical trial, outpatient clinics vs. hospitalised patients) and cut points used to define preserved function. There is an expanding body of literature about prevalence and prognostic significance of both cardiovascular and non-cardiovascular comorbidities in HFpEF patients. Current therapeutic approaches are targeted towards alleviating the symptoms, treating the associated comorbid conditions, and reducing recurrent hospital admissions. There is lack of evidence-based therapies that show a reduction in the mortality amongst HFpEF patients; however, an improvement in exercise tolerance and quality of life is seen with few interventions. In this review, we highlight the epidemiology and current treatment options for HFpEF.